Skip to main content
Pharmicell Co.,Ltd. logo

Pharmicell Co.,Ltd. — Investor Relations & Filings

Ticker · 005690 ISIN · KR7005690003 KO Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2026-02-19 Regulatory Filings
Country KR South Korea
Listing KO 005690

About Pharmicell Co.,Ltd.

https://www.pharmicell.com/eng/

Pharmicell Co., Ltd. is a biopharmaceutical company specializing in stem cell technology and advanced bio-based materials. The company is a pioneer in regenerative medicine, having developed Hearticellgram-AMI, the world's first approved stem cell therapy for acute myocardial infarction. Its core business includes the development of stem cell therapeutics, a stem cell banking service for adult and cord blood cells, and a line of cosmetics based on stem cell culture media. A significant division focuses on fine chemicals, manufacturing and supplying critical raw materials for the pharmaceutical industry, such as nucleosides, mPEGs, and oligonucleotides for gene therapies. The company also produces eco-friendly flame retardants for industrial use.

Recent filings

Filing Released Lang Actions
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) by Pharmicell. It details the contract value, counterparty (Doosan Electronics BG), contract period, and payment terms. Since this is a specific regulatory disclosure regarding a material business contract and does not fit into the other specialized categories like M&A or financial reports, it falls under the general regulatory filing category.
2026-02-19 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Audit Report / Information Classification · 95% confidence The document is a regulatory filing from a Korean company (Pharmicell) announcing a significant change (over 30%) in revenue or profit structure. This is a standard disclosure requirement in the Korean stock market (KRX) for preliminary financial results before the final audit report is filed. Since it provides key financial highlights and performance metrics for the fiscal year, it falls under the Earnings Release (ER) category, as it serves as the initial announcement of financial results. FY 2025
2026-02-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (Korea). It details the share ownership changes of a specific director (Kim Hyun Soo) of Pharmicell Co., Ltd. This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) report, as it documents insider transactions (in this case, an open-market purchase).
2026-01-28 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) filed with the Korean regulatory authority (DART). It details specific share transactions (장내매수 - open market purchase) by a major shareholder (Kim Hyun-soo) and provides a summary of the total shareholding status of major shareholders. This falls under the category of Major Shareholding Notification as it tracks changes in significant ownership levels.
2026-01-28 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in accordance with Article 147 of the Capital Markets Act in South Korea. It details changes in share ownership by a major shareholder (Kim Hyun Soo) and special related parties, including the purpose of holding (influence on management) and specific transaction details (market purchases). This type of filing is a standard regulatory disclosure for significant changes in share ownership, which falls under the 'Major Shareholding Notification' category.
2026-01-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used to disclose insider shareholdings and changes in ownership by company directors or major shareholders. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives.
2026-01-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.